+

PE20050766A1 - NEW POLYMORPHIC FORMS OF ONDASETRON, PROCEDURES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Google Patents

NEW POLYMORPHIC FORMS OF ONDASETRON, PROCEDURES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Info

Publication number
PE20050766A1
PE20050766A1 PE2005000081A PE2005000081A PE20050766A1 PE 20050766 A1 PE20050766 A1 PE 20050766A1 PE 2005000081 A PE2005000081 A PE 2005000081A PE 2005000081 A PE2005000081 A PE 2005000081A PE 20050766 A1 PE20050766 A1 PE 20050766A1
Authority
PE
Peru
Prior art keywords
ondasetron
procedures
preparation
pharmaceutical compositions
compositions containing
Prior art date
Application number
PE2005000081A
Other languages
Spanish (es)
Inventor
Barjoan Pere Dalmases
Carandell Lluis Sola
Olle Francesc Alcobe
Vallet Maria Cristina Puigjaner
Original Assignee
Inke Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34802828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050766(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inke Sa filed Critical Inke Sa
Publication of PE20050766A1 publication Critical patent/PE20050766A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA FORMA POLIMORFICA C DE ONDANSETRON BASE, CARACTERIZADA POR SU DIFRACTOGRAMA DE RAYOS X EN POLVO PRESENTA PICOS CARACTERISTICOS A 14,97° Y 20, 86° 2q Y NO PRESENTA PICOS POR DEBAJO DE 6,5° 2teta . FORMA POLIMORFICA D DE ONDANSETRON BASE CARACTERIZADA POR EL HECHO DE QUE SU DIFRACTOGRAMA DE RAYOS X EN POLVO PRESENTA PICOS CARACTERISTICOS A 11,29° ;14,58° ;17,16°; 18,89° ; 20,28°; 21,22°; 25,06° Y 27,49° 2teta. FORMA POLIMORFICA E DE ONDANSETRON BASE CARACTERIZADA POR EL HECHO DE QUE SU DIFRACTOGRAMA DE RAYOS X EN POLVO PRESENTA PICOS CARACTERISTICOS A 6,29° ;11,09° ;11,88; 12,69° ; 14,97° Y UN DOBLETE A (24,96°; 25,17°) 2teta. FORMA POLIMORFICA CARACTERIZADA POR EL HECHO DE QUE SU DIFRACTOGRAMA DE RAYOS X EN POLVO PRESENTA ADEMAS UN PICO A 25,50° 2tetaIT REFERS TO A POLYMORPHIC FORM C OF ONDANSETRON BASE, CHARACTERIZED BY ITS X-RAY POWDER DIFFRACTOGRAM, SHOWING CHARACTERISTIC PEAKS AT 14.97 ° AND 20.886 ° 2q AND SHOWING NO PEAKS BELOW 6.5 ° 2teta. ONDANSETRON BASE POLYMORPHIC FORM D CHARACTERIZED BY THE FACT THAT ITS POWDER X-RAY DIFFRACTOGRAM PRESENTS CHARACTERISTIC PEAKS AT 11.29 °, 14.58 °, 17.16 °; 18.89 °; 20.28 °; 21.22 °; 25.06 ° and 27.49 ° 2nd tit. POLYMORPHIC E FORM OF ONDANSETRON BASE CHARACTERIZED BY THE FACT THAT ITS POWDER X-RAY DIFFRACTOGRAM PRESENTS CHARACTERISTIC PEAKS AT 6.29 °, 11.09 °, 11.88; 12.69 °; 14.97 ° AND A DOUBLE A (24.96 °; 25.17 °) 2nd tit. POLYMORPHIC FORM CHARACTERIZED BY THE FACT THAT ITS POWDER X-RAY DIFRACTOGRAM ALSO PRESENTS A PEAK AT 25.50 ° 2t

PE2005000081A 2004-01-21 2005-01-20 NEW POLYMORPHIC FORMS OF ONDASETRON, PROCEDURES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PE20050766A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200400115A ES2238001B1 (en) 2004-01-21 2004-01-21 NEW POLYMORPHIC FORMS OF ONDANSETRON, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS ANANTIMETICS.

Publications (1)

Publication Number Publication Date
PE20050766A1 true PE20050766A1 (en) 2005-12-14

Family

ID=34802828

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000081A PE20050766A1 (en) 2004-01-21 2005-01-20 NEW POLYMORPHIC FORMS OF ONDASETRON, PROCEDURES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Country Status (8)

Country Link
EP (1) EP1709033A1 (en)
JP (1) JP2007518791A (en)
KR (1) KR20060127892A (en)
AR (1) AR047435A1 (en)
ES (1) ES2238001B1 (en)
PE (1) PE20050766A1 (en)
TW (1) TW200528100A (en)
WO (1) WO2005080381A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2404919E (en) 2005-11-08 2013-10-22 Vertex Pharma Heterocyclic compound useful as a modulator of atp-binding cassette transporters.
EP2444072A3 (en) 2006-10-02 2014-05-07 Labtec GmbH Non-mucoadhesive film dosage forms
NZ599889A (en) 2007-12-07 2013-09-27 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CN103025321A (en) 2010-03-23 2013-04-03 生物联合制药公司 Fast dissolving drug delivery systems
EP2377526A1 (en) 2010-03-23 2011-10-19 BioAlliance Pharma Fast dissolving drug delivery systems
JP2013523833A (en) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド 3- (6- (1- (2,2-difluorobenzo [D] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid pharmaceutical composition and Its administration
NZ720958A (en) 2013-11-12 2022-02-25 Vertex Pharma Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1182150B (en) * 1984-01-25 1987-09-30 Glaxo Group Ltd TETRAIDROCARBOZOLONICI HETEROCYCLIC COMPOUNDS, PROCEDURES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AU2003223763A1 (en) * 2002-04-30 2003-11-17 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
ES2199061B1 (en) 2002-06-10 2005-02-16 Laboratorios Vita, S.A. TROUBLE-BASED TABLETS AND PROCEDURE FOR OBTAINING.
FI6164U1 (en) 2003-01-09 2004-03-15 Synthon Bv Ondansetronformer
DE20312772U1 (en) * 2003-08-19 2003-10-30 Synthon Bv New solid, crystalline forms of ondansetron, useful e.g. for treating emesis, migraine or schizophrenia, having specific endothermal melting peak, base content or water content

Also Published As

Publication number Publication date
WO2005080381A1 (en) 2005-09-01
TW200528100A (en) 2005-09-01
EP1709033A1 (en) 2006-10-11
ES2238001A1 (en) 2005-08-01
AR047435A1 (en) 2006-01-18
KR20060127892A (en) 2006-12-13
ES2238001B1 (en) 2006-11-01
JP2007518791A (en) 2007-07-12

Similar Documents

Publication Publication Date Title
AR116052A2 (en) CRYSTALLINE FORM OF (-) - (1R, 2R) -3- (3-DIMETHYLAMINO-1-ETHYL-2-METHYLPROPYL) -PHENOL HYDROCHLORIDE
CL2012002945A1 (en) Compounds derived from amino-pyridazines; pharmaceutical compositions comprising them; and its use for the treatment of a disease selected condition of neuromuscular disorders, amyotrophic lateral sclerosis, myasthenia gravis, among others.
ZA202007679B (en) Pharmaceutical combination, composition, and combination formulation comprising glucokinase activator and sglt-2 inhibitor and preparation methods and uses thereof
NI200800294A (en) NEW CRYSTALLINE VI FORM OF AGOMELATIN, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT.
DOP2006000243A (en) PIRAZINE DERIVATIVES
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
UY33075A (en) CYCLHEXAN DERIVATIVES AND USES OF THE SAME
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
CL2007003100A1 (en) COMPOUNDS DERIVED FROM PIRIMIDINA, INHIBITORS OF CISTEINE PROTEASA; PREPARATION PROCESSES; SALES OF COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF MALARIA.
ATE528989T1 (en) CRYSTALLINE SOLID RASAGILIN BASE
NO20080784L (en) Histondeacetylaseinhibitorer
AR047088A1 (en) CRYSTALLINE POLYMORPH OF PYRIDINETILENNAFTOFURANO AS AN ANTGONIST OF THE THROMBINE RECEPTOR, METHOD OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS
WO2007031933A3 (en) Stable pharmaceutical composition comprising a pyrimidine-sulfamide
CU20060037A7 (en) GAMMA CRYSTAL FORM OF IVABRADINE CHLORHYDRATE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CL2011001658A1 (en) Sulfonamide derivatives, sodium channel modulators; pharmaceutical composition comprising them; and its use in the treatment of pain.
EA201290982A1 (en) PHARMACEUTICAL COMPOSITIONS, PREVENTING ABUSE
NI201100076A (en) THERAPEUTIC ANTIVIRAL PEPTIDES.
CO5580827A2 (en) RIMONABANT POLYMORM FORM, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
EP1861357A4 (en) Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
ECSP099442A (en) DERIVATIVES OF HETEROARIL-PIRROLIDINIL- AND -PIPERIDINIL-CETONA
CY1118976T1 (en) CRYSTAL MODIFICATIONS OF (1R, 2R) -3- (3-DIMETHYLAMINE-1-ETHYL-2-Methyl-propyl) -phenol
UY33348A (en) FUROPIRIDINE COMPOUNDS AND USES OF THE SAME
CO6321280A2 (en) NEW ESPIRO PIPERIDINAS CLASS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
PE20050766A1 (en) NEW POLYMORPHIC FORMS OF ONDASETRON, PROCEDURES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR065979A1 (en) SOLID FORMS OF THE OXYM OF THE (E) - 1- (4 - ((1R, 2S, 3R) - 1,2,3,4, - TETRAHYDROXIBUTE) - 1H - IMIDAZOL - 2 - IL) ETANONA

Legal Events

Date Code Title Description
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载